» Articles » PMID: 30428547

Next-Generation Service Delivery: A Scoping Review of Patient Outcomes Associated with Alternative Models of Genetic Counseling and Genetic Testing for Hereditary Cancer

Overview
Journal Cancers (Basel)
Publisher MDPI
Specialty Oncology
Date 2018 Nov 16
PMID 30428547
Citations 47
Authors
Affiliations
Soon will be listed here.
Abstract

The combination of increased referral for genetic testing and the current shortage of genetic counselors has necessitated the development and implementation of alternative models of genetic counseling and testing for hereditary cancer assessment. The purpose of this scoping review is to provide an overview of the patient outcomes that are associated with alternative models of genetic testing and genetic counseling for hereditary cancer, including germline-only and tumor testing models. Seven databases were searched, selecting studies that were: (1) full-text articles published ≥2007 or conference abstracts published ≥2015, and (2) assessing patient outcomes of an alternative model of genetic counseling or testing. A total of 79 publications were included for review and synthesis. Data-charting was completed using a data-charting form that was developed by the study team for this review. Seven alternative models were identified, including four models that involved a genetic counselor: telephone, telegenic, group, and embedded genetic counseling models; and three models that did not: mainstreaming, direct, and tumor-first genetic testing models. Overall, these models may be an acceptable alternative to traditional models on knowledge, patient satisfaction, psychosocial measures, and the uptake of genetic testing; however, particular populations may be better served by traditional in-person genetic counseling. As precision medicine initiatives continue to advance, institutions should consider the implementation of new models of genetic service delivery, utilizing a model that will best serve the needs of their unique patient populations.

Citing Articles

The Implementation and Outcomes of Personalized Antihypertensive Therapy Based on Pharmacogenetic Testing: A Retrospective Study Examining Blood Pressure Control and Medication Tolerability.

Khan Y, Shanmugar S, Ahmad U, Mansoor A, Gbamgbola T, Farooq W Cureus. 2024; 16(11):e74288.

PMID: 39717305 PMC: 11664490. DOI: 10.7759/cureus.74288.


Evidence-based advancements in breast cancer genetic counseling: a review.

Batool Z, Kamal M, Shen B Breast Cancer. 2024; 32(2):258-277.

PMID: 39688807 DOI: 10.1007/s12282-024-01660-9.


Using a behaviour-change approach to support uptake of population genomic screening and management options for breast or prostate cancer.

Fehlberg Z, Fisher L, Liu C, Kugenthiran N, Milne R, Young M Eur J Hum Genet. 2024; 33(1):108-120.

PMID: 39532988 PMC: 11711511. DOI: 10.1038/s41431-024-01729-1.


Uptake of Cancer Genetic Services for Chatbot vs Standard-of-Care Delivery Models: The BRIDGE Randomized Clinical Trial.

Kaphingst K, Kohlmann W, Lorenz Chambers R, Bather J, Goodman M, Bradshaw R JAMA Netw Open. 2024; 7(9):e2432143.

PMID: 39250153 PMC: 11385050. DOI: 10.1001/jamanetworkopen.2024.32143.


Genetics healthcare providers' experiences counseling patients with results from consumer genomic testing.

Trottier M, Green D, Ovadia H, Catchings A, Gruberg J, Groner V Mol Genet Genomic Med. 2024; 12(8):e2508.

PMID: 39140689 PMC: 11322993. DOI: 10.1002/mgg3.2508.


References
1.
Rahman B, Lanceley A, Kristeleit R, Ledermann J, Lockley M, McCormack M . Mainstreamed genetic testing for women with ovarian cancer: first-year experience. J Med Genet. 2018; 56(3):195-198. DOI: 10.1136/jmedgenet-2017-105140. View

2.
Weitzel J, Blazer K, MacDonald D, Culver J, Offit K . Genetics, genomics, and cancer risk assessment: State of the Art and Future Directions in the Era of Personalized Medicine. CA Cancer J Clin. 2011; 61(5):327-59. PMC: 3346864. DOI: 10.3322/caac.20128. View

3.
Hunter J, Zepp J, Gilmore M, Davis J, Esterberg E, Muessig K . Universal tumor screening for Lynch syndrome: Assessment of the perspectives of patients with colorectal cancer regarding benefits and barriers. Cancer. 2015; 121(18):3281-9. PMC: 4560979. DOI: 10.1002/cncr.29470. View

4.
Levac D, Colquhoun H, OBrien K . Scoping studies: advancing the methodology. Implement Sci. 2010; 5:69. PMC: 2954944. DOI: 10.1186/1748-5908-5-69. View

5.
Pinheiro A, Pocock R, Switchenko J, Dixon M, Shaib W, Ramalingam S . Discussing molecular testing in oncology care: Comparing patient and physician information preferences. Cancer. 2017; 123(9):1610-1616. PMC: 5400669. DOI: 10.1002/cncr.30494. View